Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) EBITDA: 2013-2025

Historic EBITDA for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to -$6.8 million.

  • Fortress Biotech's EBITDA rose 69.17% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.4 million, marking a year-over-year increase of 15.68%. This contributed to the annual value of -$110.4 million for FY2024, which is 22.46% up from last year.
  • Latest data reveals that Fortress Biotech reported EBITDA of -$6.8 million as of Q3 2025, which was up 81.33% from -$36.5 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's EBITDA ranged from a high of -$6.8 million in Q3 2025 and a low of -$62.0 million during Q4 2021.
  • For the 3-year period, Fortress Biotech's EBITDA averaged around -$28.9 million, with its median value being -$23.8 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 155.12% in 2021, then surged by 72.88% in 2023.
  • Fortress Biotech's EBITDA (Quarterly) stood at -$62.0 million in 2021, then climbed by 11.88% to -$54.6 million in 2022, then spiked by 64.10% to -$19.6 million in 2023, then decreased by 21.52% to -$23.8 million in 2024, then surged by 69.17% to -$6.8 million in 2025.
  • Its EBITDA stands at -$6.8 million for Q3 2025, versus -$36.5 million for Q2 2025 and -$22.3 million for Q1 2025.